International Journal of Heart Failure

The Korean Society of Heart Failure (대한심부전학회)
권호 표지
DOI QR코드

DOI QR Code

The Impact of the Novel Sodium-Dependent Glucose Cotransporter 2 Inhibitor, Enavogliflozin, on Cardiac Reverse Remodeling in Heart Failure Patients With Type 2 Diabetes Mellitus: A Case Series

  • Taeil Yang (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine) ;
  • Youngwoo Jang (Gachon Cardiovascular Research Institute, Gachon University) ;
  • Wook-Jin Chung (Gachon Cardiovascular Research Institute, Gachon University)
  • Received : 2024.03.21
  • Accepted : 2024.10.23
  • Published : 2024.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

Acknowledgement

This study was supported by Gachon University Gil Medical Center (FRD2023-09, FRD2022-05-02, FRD2020-11), Gachon University, College of Medicine (grant number: 202309730001), and by the "Korea National Institute of Health" (KNIH) research project (project No. 2024ER0902-00, 2021-ER0902-00, 2021-ER0902-01, 2021-ER0902-02, and 2018-ER6304-00, 2018-ER6304-01, 2018-ER6304-02) and the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (project No. 9991006834, RS-2020-KD000164).

References

  1. Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail 2023;5:82-90.
  2. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Int J Heart Fail 2023;5:66-81.
  3. Kwak SH, Han KA, Kim KS, et al. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 2023;25:1865-73.
  4. Giugliano D, Esposito K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc Diabetol 2019;18:94.
  5. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-98.
  6. Dhingra NK, Mistry N, Puar P, et al. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Fail 2021;8:4693-700.